A human story serving Parkinson's
DiamPark was born from a diagnosis. In 2018, Djamchid Dalili learned he was suffering from Parkinson's disease at age 58. Faced with the digital void experienced by patients, he founded DiamPark with one conviction: technology can — and must — improve the daily life of every person affected by this disease.
Djamchid Dalili
Founder, DiamPark
Diagnosed in 2018, at age 58
Resilience as a driver
After his diagnosis in 2018, Djamchid Dalili decided to transform this life challenge into a mission. An engineer by training, he chose to put his expertise and experience at the service of all those who live the same reality.
DiamPark was born from this resilience — a determined, human, and collective response to a global medical challenge. Because true innovation is the one that starts from lived experience.
Our mission
Improve the daily life of Parkinson's patients and optimize their care thanks to digital health, by connecting care actors around the patient.
Our vision
A world where every Parkinson's patient — regardless of age or geography — benefits from continuous, personalized, and multidisciplinary monitoring.
Our approach
Evidence-based, regulatory compliant, developed with and for patients. Nothing is deployed without prior clinical validation by our scientific committee.
Our core values
What guides us daily
DiamPark is an impact company. Our values are not slogans — they guide every decision, every feature, every collaboration.
Humanity as a Compass
Our startup was born from a lived reality. Every decision, every feature starts from the patient — their daily life, their constraints, their hopes.
An Ethics of Trust
Our approach is based on transparency and respect for the care path. Regulatory compliance, data security, and scientific honesty are our pillars.
The Rigor of Innovation
Innovation has value only if it is validated and secure. Each functional evolution of Digipark is evaluated based on its real clinical benefit.
Universal Accessibility
No age barrier, no digital divide. DiamPark is designed to be usable by all patients, including those who are not familiar with technology.
Open Collaboration
We work in partnership with university hospitals, patient associations, research laboratories, and medico-social structures to co-build the solution.
Evidence-based
Every DiamPark feature relies on clinical evidence and is developed with neurologists and physiotherapists specializing in Parkinson's disease.
The team
A committed, expert and multidisciplinary team
DiamPark brings together complementary expertise rarely gathered around the same project: digital at the service of neurology.
Neuroscience Engineers
Design of digital biomarkers and monitoring algorithms.
Expert Neurologists
Clinical validation of each feature and scientific advice.
Patient Journey Expert
Design centered on the real needs of patients and caregivers.
Developers & UX Design
Robust, secure, and scalable technical architecture — complemented by an intuitive interface accessible to all profiles and ages.
Parkinson Paramedics
Specialized physiotherapists and speech therapists, expert support.
QARA
Quality, regulatory affairs, and MDR compliance — at the heart of the approach.
Our story
From idea to medical device
Genesis — Djamchid Dalili's diagnosis
At 58, Djamchid Dalili was diagnosed with Parkinson's disease. Faced with the lack of suitable digital tools and the informational desert experienced by patients, the idea for DiamPark was born.
Development of 4 biomarkers & ICM Incubation
Development of 4 digital biomarkers: Typing (keyboard typing), Tremor (shaking), Speech (voice), Calligraphy (writing). Incubation at the Brain Institute (ICM), Paris.
CE Certification — Class I Medical Device
DiamPark obtained CE certification as a Class I medical device (MDR 2017/745) — a key step validating the scientific and regulatory rigor of the solution.
Favorable HAS Opinion — AWAKENING Project
Favorable opinion from the High Authority for Health (HAS) as part of the AWAKENING project. Integration of rehabilitation modules and enrichment of the clinical platform.
Digipark V5 Deployment & Clinical Studies
Launch of Digipark V5 with new continuous monitoring features. Start of clinical studies to validate the effectiveness of the solution on disease progression criteria.
Ecosystem of trust
Our partners
DiamPark's development is based on the support of prestigious partners in the fields of research and health.
Institut du Cerveau (ICM)
Incubator
MyBrain Technologies
Technological partner
Digital Pharma Lab
Partner
Spartners
Partner
France Parkinson
Patient association partner
Recognitions
Awards & distinctions
Prix Galien France
WinnerOne of the most prestigious distinctions in pharmaceutical innovation and digital health, awarded by an independent jury of scientists, doctors, and pharmacists. DiamPark rewarded for its digital biomarkers serving precision neurology.
MedIntech 'Coup de Cœur' Trophy
Awarded during the MedIntech trophies, rewarding the most promising innovations in the medical device and e-health sector in France.
2022
Health1tech Innovation Award
International distinction highlighting the clinical impact and patient-centered approach of DiamPark in monitoring Parkinson's disease.
2023
Brain Institute (ICM) Incubation
Selection and incubation by the largest French neuroscientific research center, located at Pitié-Salpêtrière, Paris.
2020
Resources
White Paper & scientific publications
Find here the documentary resources of DiamPark and the scientific publications that base our approach.
DiamPark White Paper
Digital Health & Parkinson's Disease
Overview of the issues, state of the art of digital solutions, and DiamPark's vision for the future of Parkinson's monitoring.
The White Paper is intended for professional use. For any regulatory documentation request, contact us at support@diampark.io
Scientific publications
Validation of digital biomarkers in Parkinson's disease
Revue Neurologique · 2025
DiamPark Clinical Study — Digital Monitoring of Parkinson's Disease
ClinicalTrials.gov · 2024
DiamPark — Digital biomarkers and ecological monitoring of Parkinson's disease: feasibility results
JNLF 2025 · French Language Neurology Days · 2025
Other scientific publications are available on request. Contact us at support@diampark.io
Contact
Let's talk together
Whether you are a patient, caregiver, health professional, association, researcher or simply curious — we are listening to you. Every message counts and contributes to improving our solution.